Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Biofrontera Yönetim

Yönetim kriter kontrolleri 0/4

Biofrontera's CEO'su Hermann Luebbert, May2023 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 1.28M olup, şirket hissesi ve opsiyonları dahil olmak üzere 37.1% maaş ve 62.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.76% ine doğrudan sahiptir ve bu hisseler € 86.61K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.9 yıl ve 1.9 yıldır.

Anahtar bilgiler

Hermann Luebbert

İcra Kurulu Başkanı

US$1.3m

Toplam tazminat

CEO maaş yüzdesi	37.1%
CEO görev süresi	less than a year
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Hermann Luebbert'un ücretlendirmesi Biofrontera'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$1m	US$475k	-US$640k
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$26m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$1m	US$18k	-US$38m

Tazminat ve Piyasa: Hermann 'nin toplam tazminatı ($USD 1.28M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 503.65K ).

Tazminat ve Kazançlar: Hermann şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Hermann Luebbert (67 yo)

less than a year

Görev süresi

US$1,278,232

Tazminat

Dr. Prof. Hermann Luebbert, Ph.D. is a Co-Founder of Biofrontera AG and served as its Chief Executive Officer since 1997 until December 13, 2021 and served as its Chairman of Management Board since 2000 un...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hermann Luebbert	Chairman	less than a year	US$1.28m	0.76% $ 86.6k
Eugene Leffler	Chief Financial Officer	less than a year	US$316.32k	Veri yok
Erica Gates	Senior Director of Finance & Principal Accounting Officer	no data	Veri yok	Veri yok
Jon Lyons	Vice President of Scientific & Medical Affairs	less than a year	Veri yok	Veri yok
Alycia Torres	Vice President of Administration	1.8yrs	Veri yok	Veri yok
Daniel Hakansson	General Counsel & Head of Compliance	4.8yrs	Veri yok	Veri yok
Samantha Widdicombe	Senior Director of Strategic Accounts & Communications	less than a year	Veri yok	Veri yok
Mark Baldyga	Vice President of & Marketing	no data	Veri yok	Veri yok
Anthony Takazawa	Executive Officer	no data	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: AI10 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hermann Luebbert	Chairman	8.6yrs	US$1.28m	0.76% $ 86.6k
John Borer	Director	1.9yrs	US$93.55k	Veri yok
Heikki Lanckriet	Director	less than a year	Veri yok	Veri yok
Kevin Weber	Director	1.6yrs	US$79.53k	Veri yok
Beth Hoffman	Independent Director	1.9yrs	US$93.04k	Veri yok

1.9yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AI10 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Biofrontera Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biofrontera Inc., Annual General Meeting, Jun 12, 2024

Biofrontera Inc., Annual General Meeting, Dec 20, 2023

Biofrontera Inc. Appoints Heikki Lanckriet to Its Board of Directors

Biofrontera Inc. Announces Resignation of Erica Monaco, Chief Executive Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Biofrontera Inc. to Report Q2, 2024 Results on Aug 14, 2024

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. to Report Q1, 2024 Results on May 15, 2024

Biofrontera Inc., Annual General Meeting, Jun 12, 2024

Biofrontera Inc. to Report Q4, 2023 Results on Mar 15, 2024

Biofrontera Inc. announced that it has received $8 million in funding

Biofrontera Inc. announced that it expects to receive $8 million in funding

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Nasdaq Determines to Grant Biofrontera Inc. an Extension of 180 Calendar Days from November 22, 2023 to Regain Compliance

Biofrontera Inc. has filed a Follow-on Equity Offering in the amount of $4.5 million.

Biofrontera Inc. to Report Q4, 2023 Results on Mar 06, 2024

Biofrontera Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Continued Listing Requirement Under Nasdaq Listing Rule 5550(b)(1)

Biofrontera Inc., Annual General Meeting, Dec 20, 2023

Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023

Biofrontera Inc. to Report Q3, 2023 Results on Nov 09, 2023

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Biofrontera Inc. Affirms Guidance for 2023

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-Pdt for the Treatment of Basal Cell Carcinoma

Biofrontera Inc. to Report Q2, 2023 Results on Aug 11, 2023

New minor risk - Profitability

Biofrontera Inc. Provides Preliminary Revenue Guidance for the Second Quarter, First Half and Full-Year of 2023

Biofrontera Inc. Appoints Heikki Lanckriet to Its Board of Directors

Biofrontera Announces 1-For-20 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Biofrontera Notifies Nasdaq Regarding its No Longer in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.33 profit in 1Q 2022)

Biofrontera Inc. Announces Resignation of Erica Monaco, Chief Executive Officer

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: US$0.024 loss per share (vs US$4.28 loss in FY 2021)

Less than half of directors are independent

Forecast breakeven date pushed back to 2024

Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Forecast breakeven date moved forward to 2022

Less than half of directors are independent

Biofrontera Inc. Revises Revenue Guidance for the Year 2022

Biofrontera Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biofrontera Inc., Annual General Meeting, Dec 12, 2022

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

Biofrontera Inc. Reports Preliminary Product Revenues for the Third Quarter and Nine Months Ended September 30, 2022

Biofrontera Inc. Appoints Gerard Digirolamo as National Sales Director

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.46 loss in 2Q 2021)

Biofrontera Inc. Provides Earnings Guidance for the Fiscal Year of 2022

Biofrontera Inc. to Report Q2, 2022 Results on Aug 12, 2022

Biofrontera Inc. Provides Revenue Guidance for the Second Quarter and Six Months Ended June 30, 2022

Biofrontera Inc.(NasdaqCM:BFRI) dropped from Russell Microcap Value Index

Biofrontera Inc. Appoints Kevin D. Weber to the Nominating and Corporate Governance, Audit and Compensation Committees

Biofrontera Inc. Appoints Kevin D. Weber to the Nominating and Corporate Governance, Audit and Compensation Committees

Biofrontera Inc. announced that it has received $9.40068 million in funding

Biofrontera Inc. announced that it expects to receive $9.40225 million in funding

First quarter 2022 earnings released: EPS: US$0.33 (vs US$0.44 loss in 1Q 2021)

Biofrontera Inc. Re-Affirms Earnings Guidance for 2022

Biofrontera Inc. to Report Q1, 2022 Results on May 13, 2022

Less than half of directors are independent

Full year 2021 earnings released: US$4.28 loss per share (vs US$479 loss in FY 2020)

Forecast to breakeven in 2023

High number of new and inexperienced directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş